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HMG-CoA reductase inhibitors (statins) are pharmaceuticals that are utilized for the 
treatment of lipid disorders along with the primary and secondary prevention of coronary 
heart disease. HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis, 
converting HMG-CoA to mevalonate. The isoprenoid products, farnesyl pyrophosphate 
(FPP) and geranylgeranyl pyrophosphate (GGPP), are derived from the mevalonate 
pathway and serve as substrates in the prenylation of 2% of cellular proteins including the 
Rho family of low molecular weight G-proteins which mediate multiple cellular signals. 
Prenylation is an important post-translational modification of proteins that plays a role in 
the subcellular localization of proteins to certain hydrophobic (membrane) compartments. 
This localization can affect overall protein function. We demonstrate that manipulation of 
the prenylation state of Rac2 alters the formation of a signaling complex between Rac2 
and Myosin IIA that forms via !2 integrin engagement coupled to chemokine (CCL2, 
MCP-1) stimulation.  This complex appears critical to the translocation of the RNA 
binding protein, HuR, from the nucleus to the cytosol whereby it functions to exact its 
effects on mRNA stability.  HuR translocation prolongs the half-life of transcripts 
encoding critical inflammatory, immune and angiogenic cytokines like TNF-", INF-#, 
and VEGF-A.  This pathway may represent a pleiotropic effect of statin therapy and may 
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Pleiotropic Effects of Statins 
Strictly defined, pleiotropy is the phenomena where a single gene has multiple 
phenotypic effects.  The same process can be and has been applied to pharmacologic 
agents, like statins.  It is well recognized that the targeted effect of statins, or HMG-CoA 
reductases, is the inhibition of cholesterol synthesis downstream of mevalonate. 
However, in addition to the well-characterized lipid lowering effects, multiple beneficial 
off-target effects have been established over the last 25 years of clinical experience. 
Examples to be reviewed here include actions on endothelial cells, antioxidant effects, 
effects directly on leukocytes, effects on plaque stability, anti and pro-angiogenic effects, 
and effects directly on the cardiac myocardium (1).  
 
The effect of statins on endothelial cell function has been linked to the direct effects 
statins have on endothelial nitric oxide synthase (eNOS) activity, subsequent NO 
production and inhibition of endothelin-1 (ET-1) synthesis (2). In regards to eNOS 
activity, there have been numerous studies supporting that statins increase mRNA 
stability of eNOS providing protection during times of vascular insult which include 
conditions of hypoxia, increased ox-LDL, and elevated IL-1 and TNF-! levels (3). 
Statins, particularly atorvastatin, have also been shown to inhibit the production of a 
protein named caveolin-1 (4). Caveolin-1 is a potent inhibitor of eNOS activity. Statins 






By both in vivo and in vitro studies, statins have antioxidant activity by decreasing the 
amount of reactive oxygen species (ROS). The mechanism involves the inhibition of p21 
Rac isoprenylation, which affects its key functional role the NADPH oxidase system of 
endothelial cells and reduces the production of ROS (5).  
 
There is evidence to support the hypothesis that statins exert a direct inhibition of 
leukocyte activation. Though the mechanism of this inhibition is not clear, there are 
several possibilities for how this might occur.  First, statins directly reduce the expression 
of adhesions molecules, particularly intracellular adhesion molecule -1 (ICAM-1) on 
endothelial cells (6). ICAM-1 is critical for the adhesion, activation, and transendothelial 
migration of the leukocyte from the vasculature. Further, it is known that integrin 
adhesion is dependent on small GTPase Rho activation (7). The dependence of Rho 
activation on isoprenylation provides a potential interventional site for statins. Finally, 
certain statins, including lovastatin and simvastatin, directly inhibit leukocyte endothelial 
binding through a specific binding site on expressed adhesion molecules such as LFA-1 
(8).  The significance of these effects may be a crucial part of the non-lipid lowering 
contributions to beneficial cardiovascular outcomes. This thesis will attempt to expand on 
the function of a small G-protein that further elucidates this premise.  
 
Statins have been shown to have multifaceted effects that promote plaque stability. One 
important mechanism of statins is the ability to decrease scavenger receptor expression 
and ox-LDL uptake by macrophages (9). A decrease in ox-LDL uptake reduces foam cell 




that they inhibit the macrophage ability to migrate in plaque and produce matrix 
metalloproteinases (MMP), which are necessary for the degradation of extracellular 
matrix (10). The net effect of MMP modulation on plaque stability is still debated but 
provides another avenue for explanation of the statin contribution to plaque instability.  
 
Statins may be involved in numerous aspects of angiogenesis in a dose dependent 
manner, although the exact role of statins in angiogenesis is debated (11). Statins have 
been implicated in the mobilization and maturation of endothelial progenitor cells 
(EPC’s), which are important in contributing to endothelial regeneration at sites of 
vascular stress. Risk factors like hypertension, hypercholesterolemia, and diabetes are 
associated with decreased levels of EPC’s. Statin therapy appears to counteract this effect 
(12).  
 
The role of vascular endothelial growth factor (VEGF) is interesting and controversial.  
VEGF is known to have positive effects on vascular remodeling, but prior studies 
demonstrate that statins decrease the plasma concentration of VEGF (13). This is a 
seemingly paradoxical effect when considering factors in cardiovascular mortality and 
morbidity. Studies done in apolipoproteinE/ apolipoprotein B-100 mice with different 
statin types may begin to shed light on this paradox. 
 
Moving from animal models to the clinic, there are numerous trials that have established 
the vascular and cardio protective effect of statins particularly in regards to acute 




4162 patients to either pravastatin or atorvastatin and found a 28% reduced risk in 
composite death, MI or rehospitalization for recurrent ACS for subjects in the statin 
treatment group (14). The Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin (or Jupiter) trial examined people with 
elevated CRP levels, as a marker for inflammatory state, but relatively normal lipid 
levels, and determined that people who took statins has a 40% relative risk reduction for 
heart attack, stroke and death after 1 year (15). This study raises further questions about 
the role inflammation has in cardiac and vascular disease.  
 
Characterization and Functional Role of Rac2 in Cell Signaling 
Rac2 is part of the Rho subfamily small GTPases (16). There are six subfamilies that 
include the RhoA-related subfamily (RhoA, RhoB, RhoC), the Rac1-related subfamily 
(Rac1, Rac2, Rac3, and RhoG), the CDC42 related subfamily (CDC42, g25k, tc10, tcl, 
chp/wrch-2 and wrch-1) the RnD subfamily (Rnd1, Rnd2, and RhoE/Rnd3), the RhoBTB 
subfamily and the Miro subfamily (17). Specifically in the Rac1 subfamily, 88% 
homology of sequence is shared between Rac1, 2, and 3 with major differences lying in 
their C-terminal residues. Traditionally, this family of proteins is thought to share similar 
functions as molecular switches with two forms that predominate; a GTP-bound (active) 
and a GDP-bound (inactive). The transition between GTP to GDP bound states of the 
GTPase is regulated by two groups of proteins. One group is called the guanosine 
nucleotide exchange factors or (GEF’s) which serve to bind the GTPases with GTP. This 
group has a Dbl - homology (DH) domain responsible for catalytic activity and a 




second groups of regulators are labeled GTPase-activating proteins (GAP’s) and serve to 
switch GTP for GDP on the GTPases. The active form of the GTPases and including 
Rac2 are thought to play a role in a variety of cellular processes including cellular 
proliferation, NADPH oxidase activity, gene expression, cell adhesion, and cell motility 
(18).  
 
There are other proteins that may have intimate roles in the functional regulation of these 
proteins. One such protein is RhoGDI. There are three Rho GDI’s, RhoGDI 1, 2, 3 or 
alpha, beta, gamma. RhoGDI 2 is LyGDI or D4GDI. These are regulatory proteins 
known to interact with Rho GTPases and regulate the localization of the Rho GTPases 
between cytosol and membrane (19). In addition they have domains that regulate the 
GTP/GDP cycling function carried out by Rho GTPases that is handled in their switch 
regions. Proteins in the GDI family make a variety of contacts with members of the Rho 
small GTPase class and may be involved in regulatory processes to varying degrees 
based on cell type and small GTPase variant.  
 
In addition to the switch regions that regulate GTP-GDP association and the contact 
points for the GDI proteins, the small GTPases have a prenylation modification that 
consists of isoprenoid products derived from the mevalonate pathway (20). Prenylation is 
an important post-translational modification of proteins that often plays a role subcellular 
localization of proteins to certain hydrophobic compartments (21). The prenylation type 
is determined by the 4th cysteine residue position from the C terminus (COOH) of the G-




alanine or threonine) motif sequence (22). The sequence will determine whether one of 
two prenylation groups, farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate 
(GGPP), will be added by a farnesylation (by fransyltransferase) or a geranylgeranylation 
(by geranylgeranyl transferase) reaction. Rac2 posses a CSLL sequence which signals a 
geranylgeranylation by the action of geranylgeranyl transferase I (23). This modification 
allows Rac 2, to remain soluble in the cytosol and associated with the GDI (Guanine 
dissociation inhibitor) or to move to the plasma membrane to mediate downstream 
signaling events (18). Multiple crystal structures of various members of the different 
GTPase families have shown interaction with the GDI molecule (24).  
 
Rac2 and other members of the small GTPase protein family have been linked to 
numerous effector proteins. A common theme among these interactions is that residues in 
the switch I region of the proteins are key for guiding reactions with different effector 
cells. For example, Rac’s interaction with p21 activated kinase (PAK) is dependent on a 
tyrosine residue at the 40th position, but another residue position determines its 
interactions with mixed lineage kinase (Mlk 2 and 3).  In addition to PAK and Mlk, Rac 
interactions have been linked to Ser/Thr kinases, PI-4-P5K, POR-1, PLD, PI3K, DAG 
kinase, PLC-B2, Wave/Scar, POSH, p67 phox, IQGAP and among others that affect a 
variety of pathways (25). These pathways include interactions with actin, SRF, JNK/p38, 
NF-kB, NADPH oxidase system, cell-cell contacts and cell cycle progression. The 
mechanism by which the small GTPases, particularly, Rac function to activate the 
effector proteins is through disruption of intramolecular auto-inhibitory domains that 




exposed allowing kinase activity to ensue.  
 
Macrophage Role in development of Vascular Disease 
Monocytes are a uniquely positioned cell type in the inflammation pathway. Their 
regulation depends partly on the activity of small GTPases that are expressed 
intercellularly.  In addition, they play a pivotal role in driving the inflammatory response 
involving plaque deposition in the vasculature. Monocytes interact with adhesion 
molecules that are expressed on the surface of endothelial cells in response to ox-LDL or 
other activators. Chemokines like monocyte chemoattractant protein 1 (MCP-1) have 
been implicated in the migration of the monocyte into the intima layer of the vessel wall 
and also drive the maturation of monocytes to macrophages (26). The maturation and 
activation of the monocyte depends partly on those chemokines, and others like 
macrophage colony stimulating factor (M-CSF) help to drive the expression of 
scavengers’ receptors on the macrophage and allow for the consumption of ox-LDL 
molecules by the macrophage. The ox-LDL is believed to bind to CD-36 and lead to 
further activation of the macrophage within the plaque (27). This activation state leads to 
the expression of many other inflammatory cytokines that in turn effect endothelial cells, 
smooth muscle cells, lymphocytes, and other macrophages. Consequently, this further 
drives the inflammatory environment and the pathology of the plaque. The structural 
integrity of the plaque is challenged by increased expression of matrix metalloproteinases 
(MMP’s) and by macrophages that degrade the components of the extracellular 
scaffolding. This is important because plaque stability plays an important role in rates of 





There is evidence that supports the significance of the different subsets of macrophages 
in the progression of atherosclerotic plague. The two subtypes of macrophages include 
M1 and M2. The M1 subtype is pro-inflammatory and expresses cytokines that include 
IL-1", TNF and IL-6. The M2 subtype has a high expression of scavenger receptors and 
might be expected to phagocytize lipid. The distinction of macrophage phenotype 
supports the timeline seen in the ApoE knockout mouse model.  In the ApoE model of 
atherosclerotic plaque development, histologic examination of vessel walls demonstrates 
that early in atherosclerotic plaque progression the M2 subtype macrophage predominates 
in lesions whereas the M1 subtype dominates in the later phases (28).   
 
Role of Chemokines in development of Atherosclerotic Plaque 
 
Several chemokine/chemokine receptor pairings have numerous studies in mice that show 
independent and additive effects on their ability to reduce the atherosclerotic burden. 
Mouse models seem to stratify the influence of the three chemokine/chemokine receptors 
into 3 major events. The first phase is macrophage recruitment, which has been linked 
primarily with CCL5, mediated stimulation of CCR5. The second phase is early 
monocyte adhesion, which has been shown to be mediated by the CCL2/CCR2 
interaction. The third phase is chronic monocyte adhesion, which has been shown to be 
supported by the fractalkine/CX3XR1 interaction (29).  
 
Monocyte chemoattractant protein 1 (MCP-1), also known as CCL2, is a key chemokine 
that promotes the migration of monocytes/macrophages. This chemokine is part of the 




chromosome 17q11.2. MCP-1 works by binding to chemokine receptors CCR2 and 
CCR11. CCR2 is a G-protein coupled receptor located on the surface of inflammatory 
cells. Binding to CCR2 results in the formation of IP3, activation of PKC, and release of 
intracellular calcium stores. CCR11 actions are less well described. The intracellular 
pathways of MCP1 signaling involve numerous downstream effector proteins that 
culminate in modulating cell activation and trafficking (26).  
  
During times of inflammatory stress, multiple cell types including endothelial cells, 
smooth muscle cells, and monocytes secrete MCP-1 and create a chemotactic 
concentration gradient for inflammatory cells to follow. Ox-LDL, but not naïve LDL, has 
been shown to induce MCP-1 production by endothelial cells and smooth muscle cells, 
which may represent the start of the recruitment of monocytes and the initiation of 
atheroma formation.  
 
CX3CL1 (also known as fractalkine) is a member of the CXC subfamily of chemokines. 
It is also an important chemokine that plays a role in immune cell trafficking. It consists 
of 397 amino acids with 5 unique domains and is encoded on chromosome 16. Its basal 
production by endothelial cells and smooth muscle cells is very low, requiring TNF-! for 
marked increase. CX3CL binds to CX3CR1, which is another G-protein coupled receptor. 
Pro-inflammatory cytokines IL-1", TNF-! and IFN-# which all are implicated in 
stimulating an NF-$B pathway that induces expression of CX3CL/CX3CR (30).  
 




infection in macrophages and other CCR5 expressing immune cells. The CCR5 gene is 
encoded on chromosome 3p21 and responses to ligands CCL3, CCL4, and CCL5 (31).  
 
Characterization, Activation and Role ofβ2 Integrin in Vascular Inflammation  
Integrin’s are defined as the cells’ connection between extracellular and intracellular 
environments (32). The signaling that occurs in integrin expressing cells is thought to be 
directional. When integrins bind, signals are sent from the extracellular domain of the 
integrin to the intracellular domains that are associated with cytoskeletal proteins and 
other intracellular effectors that act to inform the cell of its present environment. The cell 
then reacts via intracellular mechanisms to inform the extracellular component of the 
integrin that a change in affinity is needed to direct adhesion or migration. These signal 
transduction processes mediated through the integrin molecule are complex. Integrin’s 
are composed of many domains and have three prominent conformation states. Each 
integrin molecule contains an alpha and beta subunit. Each subunit contains 3 parts that 
include an N-terminal extracellular domain, a transmembrane domain and a C-terminal 
cytoplasmic domain. There are 18 different alpha subunits that can possibly join with 8 
beta subunits for different confirmations. There are two major groups of alpha subunits 
within 18 possible subunits. One group contains an !I domain while the other set does 
not. This only affects binding with potential ligands by requiring the participation of 
different beta subunits or not depending on the alpha subunit group. The key-binding site 
for the integrins is the metal ion dependent adhesion sites (MIDAS) whose conformation 
is dependent on the conformation of the !I and "I domains. These domains are important 




certain inflammatory ligands. The alpha subunit is most important in mediating the 
binding to particular ligands. In the group of integrins that do not contain the aI domain, 
ligand binding is primarily determined by the beta subunit. However, the beta subunit has 
the primary function of communicating with the intracellular domains and transmitting 
information between components. In terms of the overall conformational states the 
integrins have a bent closed, extended closed, and extended open state. Each of these 
states differs by the degree to which the ! and " subunit articulate at various extracellular 
points particularly at the headpiece region and the hybrid region.   
 
Integrins are important components of the immune effector cell. When the cell is 
recruited to a site of inflammation, it must be able to travel out of circulation and localize 
itself to specific areas around the precipitating inflammatory event. Part of this process is 
aided by the ability of the immune cell to express integrins on the cell surface. Integrins 
such as LFA-1 are able to bind to ligands like ICAM-1 that are expressed on a variety of 
cell types and help direct the immune response to localized areas. While studying cell-
cell adhesions in 1986, Springer was able to discern that LFA-1 interacted with other cell 
ligands than previously described (33). As part of his investigation of cell-cell adhesions 
he was able to determine that when LFA-1 deficient lymphocytes were incubated 
together, cell-cell adhesion would not occur in the presence of phorbol ester. However, 
when LFA-deficient cells were incubated with normal lymphocytes, adhesion was 
present indicating that a ligand other that LFA-1 was necessary for cell-cell adhesion to 
take place. Dustin et al further showed that ICAM-1 expression on dermal fibroblasts was 
increased three to five times baseline by IL-1 and TNF-alpha (34). More importantly, 




endothelial cells. Springer et al displayed LFA-1 binding to ICAM suspended in an 
artificial lipid membrane.  These discoveries have led to additional questions regarding 
whether or not LFA-1 mediated binding influenced the activation state of the immune 
cell.  
 
Members of the Bender lab have contributed significantly to the understanding of the 
integrin-mediated processes particularly in T-cells. In 2006, Wang et al. was able to 
demonstrate in human peripheral T-cells that engagement of LFA-1 leads to the 
prolongation of TNF-a, GM-CSF, IL-3 mRNA half-life and also had an effect on the 
mRNA encoding for a chimeric B-globin mRNA reporter construct containing a 
destabilizing class II AU-rich element from the GM-CSF mRNA 3’untranslated region 
(35).  In 2010, Rangolam et al. found in T-cells that LFA-1-induced stabilization of 
ARE-containing mRNA’s occurs in T-cells and was dependent on HuR. This involves a  
pathway linking Vav-1, Rac1 and 2, MKK3, and p38MAPK proteins (36). In 2012, 
Zhang et al. demonstrated that the ICAM – LFA-1 - HuR axis is key for stabilization of 
VEGF and MMP-9 labile transcripts in a macrophage model of angiogenesis (37). It is 
the role of Rac’s in the integrin induced, HuR-mediated signaling cascade and the 
importance of HuR in the macrophage inducible factor production that has led to the 
work described in this thesis.  
 
Characterization and Functional Role of Myosin IIA in Cytoskeletal Reorganization 
 
Myosin IIA is classified as a nonmuscle or atypical motor protein that associates with 




structure, Myosin IIA has three separate structural domains: globular head, neck region 
and rod (38). The first part is a globular head domain that contains regions responsible for 
actin binding. This domain also contains an enzymatic Mg+2 ATPase motor domain. The 
neck region contains an essential light chain (ELC) and a regulatory light chain (RLC). 
The ELC is responsible for stabilization of the heavy chain structure. The RLC is 
responsible for overall structure conformation, which is pivotal for actin association. The 
coiled coil rod domain allows for dimerization.  
 
On phosphorylation of the RLC, Myosin IIA transforms from a closed 10S assembly to 
an open 6S assembly that has an exposed rod domain. This rod domain is then able to 
dimerize with the rod domain of other heavy chain assemblies with concomitant actin 
interaction with the globular head domain. Studies have shown that there are two residues 
on the RLC that are important in terms of regulation. The Ser19 and Thr18 have been 
identified as two sites that are integral in promoting Myosin IIA association with actin 
through altered baseline conformational changes. Several kinases have been implicated in 
RLC phosphorylation including myosin light chain kinase (MLCK), rho associated coiled 
coil-containing kinase (ROCK), and CDC42 binding kinase CDC42BP. ROCK also acts 
to inhibit protein phosphatase 1 (PP1) which is a key dephosphorylator of Myosin IIA 
(39).  
 
Myosin IIA is a key regulator of slow retrograde flow in the lamellum, which is part of 
the leading edge of motile cells (39). When Myosin IIA is knocked down or inhibited 




This finding is key to understanding the overall role for myosin in cell motility. Myosin 
IIA also has a role in insuring proper cellular adhesion via its interaction with a variety of 
other proteins linked to integrins. In the traditional model, integrins are associated with 
actin/myosin clusters via actin linkage proteins that include !-actinin, talin and viniculin. 
Interactions between these proteins are important for the activation of a variety of kinases 
(focal adhesion kinase, Src, paxillin) that transmit downstream signals through small 
GTPase mediated pathways. 
 
In vitro studies involving Rac 1 address this point. Leeuwen et al showed that in the 
presence of bradykinin stimulation, Rac1 was activated and regulated the calcium 
dependent phosphorylation of MSII in PC12 and N1E-115 cells (40). This 
phosphorylation led to increased cell spreading through the reorganization of the 
cytoskeletal elements. Notably, this change in phenotype was in contrast to Rho mediated 
cell rounding suggesting a possible inhibition of Rho mediated cytoskeletal 
reorganization. In terms of releasing contacts made by cell adhesion molecules, the role 
of Myosin IIA has also been explored. Morin et al. showed in lymphocytes that 
disrupting the interaction of LFA-1 with Myosin IIA resulted in an inability of 
lymphocytes to disengage interactions with ICAM-1 at the uropod (41). After inhibition 
with blebbistatin or siRNA knockdown, the lymphocytes displayed a more elongated 
phenotype and a decreased inability to migrate on ICAM1/CXCL-12 slides compared to 





As mentioned above, blebbistatin, which is a highly specific inhibitor of Myosin IIA was 
used in many assays. Blebbistatin is a small molecule, uncompetitive, inhibitor that 
preferentially binds to the ADP+P bound form of Myosin IIA at the head region. It does 
not interfere with actin myosin binding or ATP induced actin myosin dissociation (42).  
 
Leukocyte HuR Regulation in Integrin induced RNA Stabilization 
 
Human antigen R or HuR is an RNA binding protein that is a member of the embryonic 
lethal abnormal vision (ELAV) family of proteins (43). It is expressed in a variety of cell 
types and is detected in both the nucleus and cytoplasm. It is involved in insuring the 
stabilization of many short-lived mRNA’s that contain AU (adenylate and uridylate) rich 
elements (AREs). This process is key in the important steps involved in gene expression. 
Post-transcriptional modification of mRNA can occur on many levels that involve the 
processes of translocation, translation, editing, and degradation of the mRNA molecule. 
This is particularly important in the context of the mRNA for a large number of 
inflammatory cytokines including TNF-a, IL-6 and IL1"..  
 
Many potential pathways have been explored to elucidate HuR shuttling. Studies 
examining the role of AMPK in decreased HuR shuttling or increased HuR nuclear levels 
show that AMPK activation serves as a unifying pathway in many potential inflammatory 
or noxious cell stimuli including oxidative stress and hypoxia. However, studies of 
various potential signaling pathways have yielded no direct regulatory answers. There has 
been an important observation of the actions of importin-!, which is a key cytoplasmic 
associated protein of HuR important in the importation of the protein into the nucleus. 




importin-!, which increases its cytoplasmic levels and thus nuclear HuR levels (44). 
Other observations have helped to shed light on potential pathways involved in the 
regulation of HuR shuttling and its ability to stabilize mRNA (45). 
 
Characterization of ApoE KO mouse model in study of Atherosclerosis 
The ApoE deficient mouse model was developed to study the process of atherosclerosis 
(46,47). The Maeda group provided the original mouse strain, which today is distributed 
by Jackson Laboratory.  Murine models have a number of caveats given the animal’s 
relative differences in cholesterol physiology. At baseline, mice have high density 
lipoprotein (HDL) levels as high as 85mg/dl (48). These mice do not develop 
atherosclerotic plaques on regular chow diet and often require long intervals on a western 
diet before the development of atherosclerotic lesions. This is possible because of the 
expression of ApoE, which allows the mice to clear lipids efficiently. The ApoE 
glycoprotein is synthesized in the liver, brain, monocytes and macrophages. With the 
knockout of the ApoE gene, the mice develop atherosclerotic lesions on normal chow diet 
and develop more significant lesions in shorter time frames on high fat diets. This allows 
for study of atherosclerotic plaque development and other factors driving inflammation in 
a more practical timeframe.  
 
Despite the relative value of the ApoE deficient murine model there are several 
shortcomings that raise the question as to whether or not findings in the model can be 
completely extrapolated to humans (49). The first is the question of gender. Several 




diet. Tangirala et al have has shown that male models develop atherosclerotic lesions in 
the aorta more frequently than models of the female gender at baseline (50). In addition, 
their ApoE-/- model also displayed a trend towards higher incidence of atherosclerotic 
plaque lesions in male mice compared to female mice but the difference was not 
significant. After the study released by Tangirala there have been multiple studies that 
have shown differences in incidence and size of atherosclerotic lesions in murine aorta 
based on the timing in which the high fat diet is started and based on the gender of the 
model. The gender differences have prompted questions into whether or not estrogen 
plays a role in influencing the development of atherosclerotic plaque in the model. 
Several studies performed in the ApoE-/- model have shown that manipulation of estrogen 
levels leads to the same protective effects in the model. Elhage et al and Bourassa et al 
have demonstrated that estrogen supplementation in ApoE -/- mice leads to inhibited fatty 
streak development and reduced atherosclerotic lesion development respectively (49). 
However, several studies have also shown that estrogen manipulation leads to non-
protective effects in the ApoE -/- model. A study utilizing tamoxifen, an estrogen 
receptor agonist/antagonist based on tissue type, showed a regression of atherosclerotic 







STATEMENT OF PURPOSE AND HYPOTHESIS 
 
Cardiovascular disease is the leading cause of death in the United States (51).  A majority 
of cardiovascular disease stems from atherosclerotic coronary disease and HMG-CoA 
reductase inhibitors have remained a standard of care in primary and secondary 
prevention for the past quarter century.  Our laboratory is interested in identifying novel 
signaling pathways influenced by statins to develop new classes of therapeutics that 
target inflammation and the immune system.   
 
The hypothesis of this thesis is: 
Isoprenylation is crucial to a signaling complex between Rac2 and Myosin IIA that 
promotes the translocation of HuR from the nucleus to the cytosol. 
 
The purpose of this thesis is to: 
 1.  Demonstrate the importance of Rac2 and Myosin IIA in the translocation of 
HuR 
 2.  Demonstrate the role of "2 integrin adhesion in the formation of a signaling 
complex between Rac2 and Myosin IIA in the setting of chemokine signaling. 
 3.  Demonstrate the disruption of both the translocation of HuR and the complex 
between Rac2 and Myosin IIA in the setting of atorvastatin treatment and reversal with 
isoprenyl specific-rescue.   
We believe that this pleotropic effect of statin may help to highlight this signaling 







THP1 Cell Line 
The human leukemic cell line (THP-1) was established using blood from a 1-year-old 
boy with acute monocytic leukemia. These cells display several characteristics that define 
its monocytic phenotype. Tsuchiya et al displayed that these cells phagocytized sheep 
erythrocytes and 0.8 mm diameter latex particles (52). These cells also displayed the 
ability to activate T-lymphocytes in the presence of Con A. In addition, these cells 
display lysozyme production. Furthermore, these cells express a-naphthyl butyrate 
esterase that is inhibited by NaF, which is an established distinguishing characteristic of 
monocytic cells. These cells differentiate into a more macrophage like phenotype when 
exposed to PMA. THP1 cells were cultured in RPMI supplemented media with FBS, 
Pen/Strep/Glut with cell media replaced every 48-72 hours.   
 
C57BL/6 & Rac2KO Bone Marrow Derived Macrophages 
Bone marrow derived macrophages were isolated from the femurs and tibias of C57BL/6 
and Rac2KO mice and placed in 10ml of fully supplemented RPMI media in a 50ml 
conical tube. The fully supplemented RPMI media is 500ml RPMI, 2 µl 2-"ME, 5ml 
HEPES, 5ml Pen/Strep, 5ml L. glutamine, 5ml sodium pyruvate, 50ml FBS. Remove 
media and wash bones with 70% EtOH  (3X). Remove EtOH and wash with 1X CMF-
PBS  (3X). Grind bones in 10ml RPMI using mortar/pestle. Filter bone homogenate 
through a 40µm strainer into a new 50ml conical tube. Add 10ml RPMI to mortar/pestle 
and repeat homogenization/filter. Wash mortar/pestle with 10ml RPMI and filter this into 
the same tube. Centrifuge at 1500 RPM for 5 minute at 4°C. Aspirate supernatant and re-
suspend pellet in 2ml lysis buffer. Add 3ml ACK lysis buffer and pipette up and down 
with a glass Pasteur pipette (better yield). Incubate for 5 minute at RT. Add 10ml RPMI 
to halt lysis. Centrifuge at 1500 RPM for 5 min at 4°C. Re-suspend pellet in 5ml 1X 
CMF-PBS. Centrifuge at 1500 RPM for 5 min at 4°C. Obtain L cell media (-20°C). Re-
suspend pellet in 10ml L cell media + fully supplemented RPMI media and filter through 
a 70µm strainer. Do cell counts. After cell counts, centrifuge media at 1500 RPM for 5 
minute at 4°C. Re-suspend pellet L cell media + fully supplemented RPMI and plate 4~5 
x106 cells in 7ml media in an Optilux petri dish (100x20mm). Cell counts and plate 4x106 
cells in 7ml media in an Optilux petri dish (100x20mm). Add 4ml fresh, pre-warmed 
macrophage media (L Cell) to each plate. Macrophages may be used on days 7-9, after 
rinsing with 1xCMF-PBS, wash plates vigorously with 1x CMF-PBS containing 5mM 
EDTA 
 
Peripheral Blood Monocyte Extraction Assay 
Peripheral Blood Monocytes were isolated from healthy human volunteers (53). Draw 
blood from subject using heparinized collection tubes. Place blood into 50 ml conical 




cells for 15 minutes at 200g at room temperature. Using sterile pipet add room 
temperature 1xPBS to final volume of 40ml. Slowly layer Ficoll-Hypaque solution 
underneath the leukocyte/RBC/PBS mixture by placing tip at bottom of tube (up to 10ml 
or 3ml/10ml sample). Centrifuge 20-30 minutes in GH-3.7 rotor at 900g at 18°C no 
brake. Using sterile pipet remove upper layer that contains plasma and most of cell 
platelet function. Using another pipet transfer mononuclear lymphocyte cell layer to 
another tube “white cloudy band”. Add HBSS and centrifuge 10 minutes at 450g. 
Remove supernatant and re-suspend in HBSS. Re-suspend cells in complete RPMI-1640 
and use for assays 
 
 
Subcellular Fractionation Assay 
Goal:  
To biochemically determine Rac2 localization under non-stimulatory and stimulatory 
events.   
Reagents: 
Thermo Scientific sub-cellular fractionation kit, 1xPBS, Cytoplasmic Extraction Buffer 
(CEB), Membrane Extraction Buffer (MEB), Nuclear Extraction Buffer (NED), 
Chromatin Extraction Buffer (NED), Cytoskeletal Extraction Buffer (PEB), Tabletop 
micro-centrifuge 
Method: 
Prepare Buffer reagents according to recommendation of Thermo scientific subcellular 
fractionation kit (78840). (500:500:250:250:250) ratio for CEB, MEB, NEB, NED, PEB 
Buffers respectively. Our samples vary from 5x10^6 to 8x10^6 cells per sample so 
approximate packed cell volume is 50%l. Add halt protease inhibitor cocktail in 1:100 
ratio to each volume of buffer prior to use. Harvest cells. If suspension, spin cells down 
in original media 1500rpm, 5 min, 25°C, remove media, then wash 1x with 1X PBS 
(1500rpm, 5 min, 25°C). Remove PBS and add 500%l CEB Buffer. If adherent, remove 
media with glass pipet. Wash with 10ml 1x PBS by swirling around plate. Remove PBS 
and add 500-800%l CEB buffer directly to plate sample. Use cell scraper to dislodge 
adherent cells, swirling buffer around plate in between successive cell scrapings. Place 
sample on ice and use pipet to transfer buffer from plate to micro-centrifuge tube. Place 
sample with CEB buffer in 4°C for 10 minutes with gentle rock. Remove sample from 
4°C and micro-centrifuge for 5 minutes, 500g, 4°C. After centrifuge, transfer supernatant 
to clean pre-chilled micro-centrifuge tube. Re-suspend pellet gently in 300%l of CEB 
buffer and place in 4°C for 5 minutes with gentle rock (wash step). Centrifuge pellet for 5 
minutes, 500g, 4°C and discard supernatant. Add 500 %l of MEB buffer to pellet and re-
suspend.Vortex on highest settling for 5 seconds. Place in 4°C with gentle rock for 10 
minutes. Centrifuge sample 5 minutes, 3000g, 4°C. Remove supernatant and add to clean, 




highest setting for 3 seconds and place in 4°C for 5 minutes with gentle rock (wash step). 
Centrifuge sample 5 minutes, 3000g, 4°C and discard supernatant. Re-suspend pellet in 
250%l NEB buffer. Vortex on highest setting for 15 seconds. Place in 4°C and rock for 30 
minutes. Centrifuge for 5 minutes, 5000g, 4°C. Transfer supernatant to clean pre-chilled 
micro-centrifuge tube. Re-suspend pellet in 250%l NEB buffer with (5%l 100mM CaCl2 
and 3%l Micrococcal Nuclease per 100%l of NEB).Vortex on highest setting for 15 
seconds. Place in 37°C water bath for 5 minutes.Vortex on highest setting for 15 seconds. 
Centrifuge at 5 minutes, 16000g, room temperature. Transfer supernatant to clean micro-
centrifuge tube. Re-suspend pellet in 100%l of NEB buffer with (5%l 100mM CaCl2 and 
3%l Micrococcal Nuclease per 100%l of NEB).Vortex on highest setting for 15 seconds. 
Discard supernatant. Add room temperature PEB Buffer and vortex on highest setting for 
15 seconds. Incubate at room temperature for 10 minutes. Centrifuge for 5 min, 16000g 
and transfer to new centrifuge tube. Save fraction on ice for same day use. For extended 





Characterize association between Rac2, RhoGDI and LyGDI and localization of Rac2 
under specific stimulatory conditions by immunofluorescence (54). 
Reagents: 
Rac2 antibody - (Santa Cruz) (polyclonal) (rabbit), RhoGDI antibody - (Santa Cruz) 
(rabbit), LyGDI antibody - (Santa Cruz) (mouse and rabbit), Goat Serum IgG, Normal 
IgG - rabbit (Santa Cruz), Normal IgG - mouse (Santa Cruz), 1x PBS .3% Triton, 1x 
PBS, 4% Paraformaldehyde, 100% Methanol, 70% EtOH, 6 well glass tissue culture 
treated plate, Glass coverslips (fisherbrand 22x22-1), Microscope slides (poly-lysine 
treated), Styrofoam container with wells (leftover cuvette holder suffices), .01% w/v 
poly-l-lysine (sigma) 
Method: 
Sterilize glass coverslips in 6 well plates with 1 of two methods. 1)Add EtOH to wells 
and let sit for 15 minutes, then remove excess and let dry at room temp or overnight or 2) 
First coat slides with poly-l-lysine, then UV irradiate overnight. Coat glass coverslips 
with .01-w/v poly-l-lysine for 1 hour then remove excess. Allow glass slides to dry at 
room temp or in 37 degree. Place cells in appropriate media and experimental condition 
in each of the 6 well at 250,000 cell/ml density / 2ml total. Remove media from each of 
the wells. Wash 1x with 1x PBS Sterile. Fix cells by adding 1ml 1xPBS 4%. 
Paraformaldehyde and let sit for 15 minutes. Wash cells 3x with 1x PBS (5 min/wash). 




PBS (5min/wash). Block w/goat serum 5% by volume (50ul in 950 1xPBS, .3% triton) 1 
hour at 4°C. Incubate in primary antibody (1 to 500 antibody to 1xPBS, .3% triton) 
overnight. Wash cells 3x with 1x PBS (5 minutes/wash). Incubate cells with secondary 
antibody (alexa-flour 488/568) for 2 hours. Wash cells 3x with 1x PBS (5 minutes/wash). 
Stain cell nucleus with DAPI for 15-20 seconds. Wash cells 3x with 1x PBS. Mount cells 
with Tris-Cl mounting solution and store in dark overnight. Visualize cells.  
  
 
Rac GTPase Activation Assay 
Goal: To determine activation state of Rac2 in biochemical assay across multiple 
experimental conditions (55). 
Reagents: 
Rac2 antibody – Proteintech monoclonal, or C terminal class. THP1 cells 10x10^6 per 
plate. PBD-Pak beads. Lysis Buffer:1ml HEPES, 7.5ml NACL (1M), 500ul triton X100, 
5ml Glycerol, 400 %l EDTA, 400 %l EGTA, 35 ml h2o, protease inhibitor (1 tab per 10ml 
per aliquot), GTP#S (non-hydrolyzable GTP), RPMI Media with FBS and Pen/Strep/Glut 
Method: 
Spin down at 1500rpm for 5 minutes at 25°C. Take off excess media. Lyse Cells in lysis 
buffer 500%l (as per above). Allow cells to sit in lysis buffer on ice 5 minutes. Spin down 
at 1000g 5minutes at 4°C. Take Supernatant do protein concentration. Take 50ug per 
sample for TCL, re-suspend 4x buffer, boil, save -20°C. Take equal amount protein per 
sample and add GTP#S (100%M – 5%l in 500%l solution) for 15 minutes at 37°C. During 
this time re-suspend beads by flicking and place on ice. Add 12ul of beads to TCL from 
GTP#S treatment to beads and rock at 4°C for 40 minutes. Spin down beads 400g 2 
minutes, take off supernatant. Perform 2 washes of beads at 400g 2 minutes in lysis 
buffer. Take beads and add to 40%l of 2x sample buffer (4x dissolved with H2O 2x 
volume). Boil, run gel, transfer, Western blot for Rac2 and Myosin IIA 
 
Immunoprecipitation Assay 
Goal: Characterize association between any two desired proteins across multiple 
experimental conditions (56).  
Reagents: 
Rac2 antibody - Santa Cruz (polyclonal) (rabbit), Rac2 antibody - Millipore (polyclonal) 
(rabbit), Rho-GDI antibody - Santa Cruz (rabbit), Ly-GDI antibody - Santa Cruz (mouse 
and rabbit), IP Buffer: 25mm Tris-Cl pH 7.4, 150mm NaCl, .1% Triton X-100, 2.5mm 
EDTA, 1mm DTT, Protein A/G Beads 
Method: 
Add 4ug of IP antibodies to 40 %l of bead slurry in 500%l of PBS in 1.5 ml centrifuge 
tube and rock in 4°C overnight. Lyse 10x10^6 cells in 1 ml IP buffer 
Spin down samples at 9300g at 4°C for 10 minutes in microcentrifuge. Take supernatant. 




for 30 minutes (pre-clear). Spin down beads (6000 rpm, 6 minutes, 4°C) and take lysate. 
After overnight A/G antibody incubation spin down beads (6000rpm, 6 minutes, 4°C). 
Take off PBS supernatant. Add 500%g lysate to respective antibody samples. Rock 
sample overnight at 4°C. Wash samples 2x with IP Buffer (6000 rpm, 6 minutes, 4°C). 
Bring up in 40%l of sample buffer. Boil 4 minutes. Spin down beads at 10,000 rpm for 10 
minutes and take sample buffer. Run 20%l per lane in small gel (4-15% gradient). 
Western: Rac2, Rho-GDI, or Ly-GDI depending on experimental combination. 
 
 
ICAM Localization Assay 
Goal:  
To utilize ICAM binding as signal for Rac2 activation across many different 
experimental conditions.  
Reagents: 
Petri Dishes, 10%g/ml Goat Anti Human Igg-Fc in 50mM Tris-Cl pH 9.5 (100%l Anti 
Human Igg for 10ml Tris-Cl), IgG, Tris-CL pH 9.5  *make 1M stock Tris base and pH 
with HCL then filter sterilize, PBS-CMF, PBS + 2% dialyzed FBS 10ml in sterile 490 ml 
PBS, rH ICAM 100ng/ml (-20°C ), rH Fc (-20°C), Assay Buffer: 20mM HEPES pH 7.4, 
135 mM NaCl, 5mM KCL, 2mM Glucose, 1mM MgCl2, .6mM CaCl2, sterile filter. 4x 
Lysis Buffer: 20mM HEPES pH 7.4, 150mM NaCl, 4% TritonX100, 40% Glycerol, 
16mM EDTA, 16mM EGTA, 4 non EDTA protease inhibitor tablets 
Method: 
Coat plate with 5 %l of Igg Fc. Incubate at room temperature for 1 hour. Wash 2x with 
PBS-CMF + 2% dialyzed FBS (simple swish and suction). Block by adding 5 ml PBS + 
2% dialyzed FBS and let sit room temp for 1 hour. Take off PBS. Add 5 ml of rh ICAM 
(100ng/ml in 2% dialyzed FBS / or 1 %l rh ICAM in 10ml dialyzed FBS) Swish around to 
ensure even coating and put in 4°C overnight. If Fc plate use rh Fc (100ng/ml). Remove 
media from rh ICAM or rh Fc coated plates. Take 10 million cells and separate out into 
plates +/- PMA and incubate for 30 minutes. Prepare Assay buffer with PMA. 4ml assay 
buffer. Dilute PMA 1 to 10 in DMSO and take 2 %l add to 4ml assay buffer). After 30 
minute incubation wash cells 2x with PBS. Bring up in 1.2ml of assay buffer with PMA 
per sample. Transfer to labeled ICAM plates and place in incubator for 60 minutes. 
Gently remove assay buffer and add CEB buffer to each plate. Scrape plates and continue 
with subcellular fractionation protocol 
 
 






To determine relationship of Rac2, actin and Myosin interaction. 
Reagents: 
Rac2 ab – Protein monoclonal, Myosin Antibody, THPI cells 10x10^6 per plate 
Lysis Buffer:1ml HEPES, 7.5ml NACL (1M), 500ul triton X100, 5ml Glycerol, 400 %l 
EDTA, 400 %l EGTA, 35 ml h2o, protease inhibitor (1 tab per 10ml per aliquot), MCP-1 
(100ng/ml final concentration)  (stock is 100ng/%l), Cytochalasin D (,01%m, .1%m, 1%m 
and 10%m formulations) (5mg in 1ml stock), Blebbistatin (2%M, 10%M, 50%M 
formulations), GTP#S, 10x10^6 cells per plate, RPMI Media with FBS and 
Pen/Strep/Glut 
Method: 
Plate 10x10^6 THP1 cells per petri dish plate in 10ml media. Add 10%l MCP-1 
(100ng/ml) to each plate. Let plate sit for 10 minutes. Spin down at 1500rpm for 5 minute 
at 25°C. Take off excess media. Lyse Cells in lysis buffer 500%l (as per above). Allow 
cells to sit in lysis buffer on ice 5 minutes. Spin down at 1000g 5minutes at 4°C. Take 
Supernatant do protein concentration. Take 50%g per sample for TCL, re-suspend 4x 
buffer, boil, save -20°C. Take equal amount protein per sample and add GTP#S (100uM 
– 5ul in 500ul solution) for 15 minutes at 37°C. During this time re-suspend beads by 
flicking and place on ice. Add 12ul of beads to TCL from GTP#S treatment to beads and 
rock at 4°C for 40 minutes. Spin down beads 400g 2 minutes, take off supernatant. 
Perform 2 washes of beads at 400g 2min in lysis buffer. Take beads and add to 40%l of 2x 
sample buffer (4x dissolved with H2O 2x volume). Boil, run gel, transfer, Western blot 
for Rac2 and myosin 
 
 
Proximity Ligation Assay 
Goal:  
To characterize relationship between Rac2 and Myosin IIA. 
Reagents: 
Blocking Solution, Antibody Diluent, PLA probe (5x), Ligation Buffer (5x), Ligase 
(1U/%l), Amplification (5x), Polymerase (10U/%l), Wash buffer A, Wash buffer B, Rac2 
antibody, Myosin IIA antibody 
Method: 
Method adapted from DuoLink In Situ manual. Plate slides on cover slip and 
permeabilize. Add blocking solution to each sample. Incubate the slides in pre-heated 
chamber for 30 min at 37°C. Remove blocking solution from each sample. Add primary 
antibody to each sample. Incubate antibody in humidity chamber (variable timing). Dilute 
two PLA probes in 1:5 antibody diluent. Remove primary antibody from slides. Wash 
slides in 1X buffer x2 5 minute each time. Add PLA probe solution. Incubate slides in 
pre-heated humidity chamber for 1 hour at 37°C. Dilute ligation stock 1:5 in high purity 
water and mix. Remove PLA probe from slides. Wash slides in 1x wash buffer A 2x at 5 
minute with gentle agitation. Prepare ligase-ligation solution. Add ligase-ligation solution 
to each sample. Incubate slides in preheated humidity chamber fro 30 minutes at 37°C. 
Dilute amplification stock 1:5 in water and mix. Remove Ligase-ligation solution. Wash 




amplification-polymerase solution. Add amplification-polymerase solution to each 
sample. Incubate slides in pre-heated humidity chamber for 100 minutes at 37°C. 
Remove amplification-polymerase solution. Wash in 1x wash buffer B 2x for 10 minutes. 












































Baseline Localization of Rac2 
 
Prior studies have established a relationship between small GTPases like Rac2 and 
RhoGDI (24).  In figure 1, we utilize two protocols differing in wash conditions that 
minimize contamination of protein fractions to accurately determine Rac 2 localization 
under non-stimulatory conditions. Figure 1, vertical lane 2 shows a Rac2 signal in the 
cytoplasmic fraction. Figure 1, vertical lane 4 shows no signal in the membrane fraction. 
At baseline, Rac2 is localized to the cytosol.  Figure 1, vertical lanes 2 and 4 also show a 
signal for RhoGDI confirming its cytosolic predominance at baseline. We utilize 
immunofluorescence to establish co-localization between Rac2 and RhoGDI in untreated 
THP1 cells (Figure 2A). Consistent with earlier biochemical findings, the untreated 
THP1 cells show an overlap pattern that has a high correlation coefficient of .916 (Figure 
2B). The limitations to these findings include elevated nonspecific binding of IgG rabbit 
antibody in control slides for immunofluorescence microscopy (Figure 3A, 3C). The IgG 
rabbit is the same species as the Santa Cruz polyclonal Rac2 antibody utilized in the 
assay. Interpretation of these results may be compromised by species pre-determined 
non-specific binding and antibody quality. At the time of the experiment, the Rac2 rabbit 
polyclonal was the best antibody available and was considered the standard for Rac2 
detection. More data and exploration of the Rac2 RhoGDI association will need to be 
done to fully understand the relationship between these proteins.  
 




Isoprenylation is an important post-translational modification that effects small GTPase 
localization. To better characterize the effect of statin induced de-isoprenylation on Rac 2 
localization, we treat THP1 cells with 10%m atorvastatin. Figure 4, vertical lane 3, row 1 
shows that Rac2 localizes predominantly to the cytosol after 10%M atorvastatin treatment. 
Vertical lane 6, row 1 shows that a small fraction of Rac2 can become membrane 
associated after atorvastatin treatment. This is most likely explained by generalized 
dysregulation due to loss of isoprenylation. The deregulated state allows a small but 
detectable fraction of Rac2 to associate with the membrane. The western blot in figure 4 
also shows a signal intensity difference between the untreated, PMA, PMA+atorvastatin 
cytosolic lanes. As we discover later, this is due to the mechanism of antibody binding 
for the directed class of antibody (Figure 5A, 6). At the time of the experiment, the Santa 
Cruz antibody was considered the standard for Rac2 detection. The antibody is reacting 
to the non-isoprenylated C-terminus of Rac2 and displays a variation in prenylation level. 
The samples contain equal amounts of protein. The diminished signal of HSP90 is due to 
statin effects on HSP90 expression. Samples are treated with GTP#S, which is a 
nonhydrolyzable form of GTP that allows complete loading of Rac2 to promote the 
activated state, before and after separation to determine protein fractions that could be 
activated.  In terms of the Rac2 relationship with Rho GDI after 10%M Atorvastatin 
treatment, immunofluorescence microscopy shows a drop in the correlation coefficient to 
.875 (Figure 2B). This is most likely representative of some disruption to the Rac2 
RhoGDI interactions due to loss of isoprenylation. The same limitations to 
immunofluorescence analysis apply as stated above and more work is needed to 






Effect of !2 integrin engagement and PMA on Rac2 activation 
 
Rac2 activation is important to its cellular functions. Our experiments show that "2 
integrin engagement with PMA co-stimulation causes Rac2 activation to levels detectable 
by the activation assay (Figure 7). Figure 7 vertical lane 4 shows a detectable Rac2 signal 
by pulldown with PBD-pak domain. Notably, in vertical lane 1 & 2, the Fc portion of 
recombinant ICAM or PMA alone does not activate Rac2 to detectable levels. In vertical 
lane 3, ICAM alone shows a very small level of Rac2 activation.  Findings in Figure 7 
suggest that integrin engagement requires stimulation to the high affinity states (with 
PMA or other physiologic products) and thus the presence of integrin ligand alone is not 
sufficient to load Rac2 to detectable levels for the Rac GTPase activation assay.  
 
Mass spectrometry findings and Complex development 
 
During the course of performing many of our pulldown assays we observed non-specific 
antibody binding forming bands at roughly 40kDa and 200kDa. We provide a Coomassie 
Blue stain that displays the pattern of these bands in relation to a PMA time-course 
experiment (Figure 8). After mass spectrometry analysis, these bands were discovered to 
be actin (coverage 78.7%) and non-muscle myosin IIA (coverage 61.5%) (Figure 9). This 
result suggests that Rac2 activation in the setting of PMA could involve specific 
cytoskeletal complexes necessary for creating an apparatus conducive for downstream 
signaling.   
 





THP1 cells with 0.1, 1, 10 and 100%M atorvastatin display concentration dependent loss 
of complex formation in the setting of PMA and GTP#S (Figure 10). We observe loss of 
actin and myosin IIA signal at atorvastatin concentrations & 10%M. This observation 
correlates with an increase in signal intensity for Rac2 as shown in the pulldown row, 
suggesting loss of prenylation as measured by Rac2 c-terminal class antibody (see below 
for further detail).  In addition, the Myosin IIA signal is lost at 10%M atorvastatin. These 
results show that complex formation under the conditions of PMA + GTP#S is an 
isoprenylation dependent process.  
 
Complex formation is geranylgeranyl pyrophosphate dependent 
 
We sought to recover complex formation by providing prenylation substrates 
gernaylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP) after co-
incubation of THP1 cells with 10%M Atorvastatin over 24 hours (Figure 11). In lane 1 of 
figure 11, actin signal is at baseline while MyosinIIA signal is absent. In lane 2, complex 
formation is demonstrated with increased actin and Myosin IIA signal in the context of 
PMA stimulation. In lane 3, atorvastatin inhibits PMA induced complex formation as 
there is a drop in signal for both actin and Myosin IIA. Complex recovery is suboptimal 
in lane 4 with 5%M FPP, but near positive control levels with 5%M GGPP in lane 5 and 
complete with 5%M GGPP+5%M FPP in lane 6. In addition, the isoprenylation state of 
Rac2 is shown by western blot. Lanes 2 and 3 show loss of isoprenylation. Lanes 4 and 5 
show recovery of isoprenylation with GGPP alone or GGPP+FPP. These results support 
that the complex is dependent on isoprenylation substrate GGPP and that Rac2 





Complex formation is actin dependent 
 
We demonstrate that complex formation is dependent on actin polymerization (Figure 
12). THP1 cells were co-incubated with CCL2 and cytochalasin D. We inhibit actin 
polymerization with .1, 1, and 10%M cytochalasin D and observe a dose dependent loss 
of actin and Myosin IIA signal by western blot. This experimental result supports the 
notion that formation of the complex is dependent on actin polymerization.  In addition, 
we utilize CCL2 in place of PMA to provide a more physiologic stimulatory signal.  
 
Complex formation requires Myosin IIA 
 
Further characterization of our complex was achieved with dose dependent inhibition of 
Myosin IIA using Blebbistatin (Figure 13). Despite decreases in Myosin IIA signal by 
western blot, actin levels remained stable. This shows that actin polymerization and 
recruitment is independent of Myosin IIA recruitment to the signaling complex.    
 
Demonstration of Complex existence in BMDM and human WBC 
 
Complex formation is demonstrated in BMDMs under conditions of CCL2 coupled "2 
integrin engagement (Figure 14). The significance of this figure is that the CCL2 coupled 
"2 integrin engagement signal does not stimulate Rac1 or CDC42 association with 
Myosin IIA suggesting specificity for the Rac2-Myosin IIA interaction. Further, complex 
formation is inhibited in Rac2KO BMDM’s. To further demonstrate the existence of the 
complex in human peripheral white blood cells, a screening assay was performed. Figure 
14 shows formation of the complex under experimental conditions of PMA and GTP#S 
loading in subjects not currently taking statins. However, for subjects taking statins 




some insight into the regulation of the complex in human cells and allows a first 
molecular insight into pharmacologic statin therapy influencing this signaling complex. 
More controls and further experiments are needed to expand on this concept.  
 
Significance of Rac 2 Isoprenylation in Complex Formation 
 
The significance of Rac2 isoprenylation is an important consideration in the formation of 
the complex.  A novel aspect to antibody binding was discovered when a new 
monoclonal antibody became available for Rac2 (Figure 5A). The original Santa Cruz 
and Abcam antibodies for Rac2 were polyclonal and recognized Rac2 by binding to the 
C-terminus of the small GTPase. In states when Rac2 was isoprenylated by the GTases, 
these antibodies appear to have more difficulty binding to the C-terminus of the small 
GTPase and display a quantifiable decrease in signal. When Rac2 was non-isoprenylated 
(in the case of statin treatment), these antibodies bind readily and reproducibly to the C-
terminus. Around 2010-2011 antibodies were introduced to the market that recognized 
full recombinant Rac2 (Proteintech) and bound to the protein regardless of prenylation 
state. The differential binding provides a useful tool to access prenylation levels while 
using full protein antibodies as loading controls as shown in (Figure 5B and 6).  
 
Given this unique tool we were able to quantify the amount of time it takes for Rac2 loss 
of isoprenylation to occur. As shown in figure 16A, we observe peak effect at 24 hours 
with 10%M atorvastatin. By utilizing the Rac2 activation assay, we determined that non-
isoprenylated Rac2 is able to achieve activation secondary to dysregulation of the GDI’s 
ability to inhibit GTP loading. Our localization experiment hinted at the potential Rac2 




that non-isoprenylated Rac2 can become activated at higher concentrations than 
isoprenylated Rac2 as shown by the activation assay. This raises questions as to whether 
or not Rac2 fits in the general regulation model proposed for small GTPases.   
 
HuR translocation is dependent on CCL2 coupled !2 integrin engagement and 
inhibited by loss of prenylation 
 
Prior to use of physiologic stimuli CCL2, we utilized PMA to activate cells. In prior 
experiments, we have shown the ability of PMA coupled " integrin engagement to induce 
HuR translocation to the cytoplasm and its dependence on isoprenylation (Figure 17). 
Figure 17 row 1 shows no HuR translocation in untreated THP1 cells plated on poly-l-
lysine. In overlay in lane 1, DAPI nuclear stain and HuR stain overlap. Row 2 shows that 
PMA is insufficient to produce HuR translocation. Row 3 shows HuR translocation in 
THP1 cells treated with PMA and plated on ICAM. Row 4 shows inhibition of HuR 
translocation in THP1 cells treated with 10%M Atorvastatin, PMA and plated on ICAM. 
With the use of physiologic stimuli, we demonstrate biochemically that CCL2 coupled " 
integrin engagement and GGPP substrate are necessary for Rac2-Myosin IIA interaction 
by pulldown assay in the context of 10%M atorvastatin treatment (Figure 18A). In row 1, 
lane 1 and 2 there is no detectable pulldown of Myosin IIA in the presence of squalene or 
no precursor. In row1, lane 3 there is a minor detectable amount of MyosinIIA in 
pulldown with FPP as substrate.  In row 1, lane 4, GGPP allows for a detectable 
pulldown of Myosin IIA. In addition, there are no detectable amounts of isoprenylated 
Rac2 with GGPP rescue. We also demonstrate by confocal analysis that HuR 




(Figure 18B). With provision of prenylation substrate GGPP and GGPP+FPP, we are 
able to rescue HuR translocation in the presence of atorvastatin.  
 
Interactions between Rac2 and Myosin IIA 
 
The "2integrin induced Rac2-myosin IIA interaction is unique to the literature and was 
explored further in our experiments. Comparison of the activating signals of CCL2, 
PMA+ICAM, ICAM and ICAM+CCL2 show that the Rac2-myosin IIA interaction is 
achieved when dual signals from either CCL2 coupled "2 engagement or PMA coupled 
"2 engagement is present (Figure 19). This further reinforces a multistep process as being 
required for activation of Rac2. In order to discern if this interaction was even more 
specific, experiments were conducted in knockout mice. Figure 14 shows the specificity 
of this interaction in Rac2KO mice versus C57BL/6.  
 
To further characterize the interactions between Rac2 and myosin IIA, a proximity 
ligation assay (PLA) was utilized. Figure 20 shows the common stimulatory conditions, 
Fc alone, CCL2+Fc, ICAM alone and CCL2+ICAM used and the resultant interactions 
between Rac2 and MyosinIIA as measured by PLA. The signal is quantified by the red 
emissions. In Figure 20 row 4 lane 2, we demonstrate that "2 integrin engagement and 
CCL2 exposure promotes an interaction at a distance of 40nm between Rac2 and myosin 
IIA as indicated by the strength of signal compared to other conditions.  
 
In order to link chemokine coupled integrin engagement with HuR translocation in a 
single display, quantify results and show potential clinical significance we utilized our 




the monocytes under stimulatory conditions as shown in (Figure 21). All exhibited some 
spreading but there was a robust HuR response to CCL2 coupled "2 integrin engagement. 
The translocation factors show appreciable differences and a large percentage of cells 
under ICAM+CCL2 underwent HuR translocation compared to individual stimulators.  
 
To further characterize the importance of Rac2 and myosin IIA in the precipitation of this 
phenomenon we utilized Rac2KO and Myosin IIA KO BMDM. In figure 22, CCL2 
coupled "2 integrin induced translocation of HuR is seen in the WT C57BL/6 mice but 
not in the Rac2KO. Translocation factors are shown with percent cells with HuR 
translocation. In our myosin knockout experiment, we utilize heterozygous myosin IIA 
and myosin IIA KO mice to demonstrate that CCL2 coupled "2 integrin translocation is 
not observed in the knockout. Quantification of HuR translocation factors and percentage 

























The dysregulation of small GTPases is an important consequence of statin therapy. It is 
one of many pleiotropic effects that statins demonstrate in vitro and in vivo. Many studies 
have been completed in an attempt to explain the clinical significance of small GTPase 
dysregulation given the importance of these molecules in the function of macrophages. 
The small GTPases hold a central position in the outside in signaling of "2 integrins. 
These signaling cascades have been linked to monocyte/macrophage activation. Given 
the centrality of macrophages in the inflammatory response to plaque formation and 
progression, regulation of the small GTPase class of proteins takes on clinical 
significance. Our aim was to explore the importance of Rac2 isoprenylation and the 
significance the modification had on its localization and function.  
 
Our results show that Rac2 is a dynamic protein whose regulation is dependent on 
isoprenylation. Traditional models in the literature state that Rac2 is isoprenylated and 
bound to GDI while in the cytosol (19). These models predict that an activation signal 
causes members of the GTPase class to be dissociated from GDI and localize to the 
membrane. Once at the membrane, the small GTPases can interact with exchange factors 
that load it with GTP and allow for interaction with downstream effectors. While this 
thesis does not readdress the Rac2 RhoGDI association in the literature, we do provide 
immunofluorescent and western blot evidence that show Rac2 and RhoGDI in similar 
subcellular fractions. Using a subcellular fractionation protocol we demonstrate that Rac2 
can be localized to the membrane when provided the two signals consisting of PMA and 




requiring integrin engagement and either PMA or CCL2 exposure.  Using 
immunoflourenscent staining, we show that statin pretreatment decreases the association 
of RhoGDI with Rac2, again supporting this known relationship. 
 
When Rac2 becomes activated through a coupled CCL2-"2 integrin activation signal, a 
complex of proteins including Rac2, actin and myosin IIA are assembled. This complex 
is conserved in THP1 monocytes, BMDM, and in an initial screening of human 
peripheral blood monocytes. We demonstrate that formation of the complex is 
isoprenylation dependent. This is a key finding that underlies the purpose of studying this 
modification and this class of proteins. The dependency on isoprenylation is 
demonstrated by specific substrate supplementation with GGPP and FPP, which allows 
recovery of complex assembly after 10%M atorvastatin therapy. We are further able to 
characterize the complex as dependent on actin polymerization and myosin IIA activation 
because both cytochalasin D and blebbistatin inhibit complex formation.  
 
The formation of the complex reorganizes the cytoskeleton and creates an environment 
conducive for downstream signaling. We observe HuR translocation to the cytoplasm as 
a significant event tied to CCL2 coupled "2 integrin activation of Rac2. HuR 
translocation is significant because of its effects on stabilization of inflammatory and 
angiogenic mRNA transcripts. As mentioned above, the Bender lab has shown 
prolongation of message half-lives for transcripts that include TNF-!, IL-3, VEGF and 
MMP-9 in an HuR dependent manner (35, 36, 37). Our experiments show consistent 




variety of modalities. We also show the entire process to be isoprenylation dependent, 
which directly links the effect of statin not only to complex formation but also the 
propagation of inflammatory signals to HuR-mediated gene expression.  
 
To further characterize the determinants of HuR translocation, cells from wild type, 
Rac2KO, and Myosin IIA KO’s were utilized to discern the relative contributions of each 
protein. Knockout experiments demonstrate both Rac2 and Myosin are critical to HuR 
translocation.  In fact, bone marrow-derived macrophages from their respective knock out 
mice demonstrate phenotypic similarities in their diminished response to integrin 
signaling. Given the novelty of the Rac2-myosin IIA interaction, we conducted 
experiments to more closely study their relationship under CCL2 coupled "2-integrin 
activation. Utilizing the Proximity Ligation Assay (PLA), we were able to quantify the 
close relationship between Rac2 and Myosin IIA.  
 
There remains more to explore in the mechanisms related to regulation of Rac2 
prenylation. Our assays did not assess a time frame for cell dependent recovery of either 
isoprenylation or protein turnover. Future experiments are needed to elucidate this story.  
 
While our studies focused on a CCL2 coupled "2 integrin stimulation, more studies 
should be carried out with other important chemokines such as CCL5 and CX3CL, which 
are important in macrophage recruitment and activation in vitro and in vivo. Also, 
experiments involving oxLDL assays should be completed to better characterize the 





As more basic and clinical studies are completed, the relative contribution of the HuR 
activation event and integrin mediated signaling pathway in the progression of 
atherosclerotic plaques will be uncovered.  HuR serves as a critical molecular switch in 
gene expression with respect to the activation and differentiation of immune cells.  The 
above-described integrin-Rac-myosin axis appears to play a critical role in HuR 
activation and serves as a pleiotropic target of statin therapy.  Fully understanding the 
mechanisms behind this pleotropic effect of statins has the potential to yield Rac2 and 
myosin as potential targets for novel molecular therapeutics that modulate the immune 





































Figure 1: Baseline Rac2 and RhoGDI subcellular localization. THP1 cells were lysed 
with separation of cytoplasmic and membrane fractions utilizing thermo scientific 
subcellular fractionation buffers. Two separate subcellular fractionation protocols were 
utilized for comparison. Western blot analysis performed with anti-Rac2 (C-terminus) 















































































































Figure 2: Effect of atorvastatin on Rac2 RhoGDI interaction. A) THP1 cells were 
adhered to poly-l-lysine coverslips, permeabilized, and immunoflourescent costaining 
was performed with RhoGDI, Rac2, and DAPI for nuclear definition in untreated and 
treated samples. Treated samples were incubated on poly-l-lysine coverslips in 10%M 
atorvastatin for 24hrs at 37°C prior to permiabilization. Untreated samples were also 
incubated overnight at 37°C B) Overlap coefficients from raw images were calculated 















Figure 3: Immunofluorescence characterization of controls. A) THP1 cells were 
adhered to poly-l-lysine coverslips, permeabilized, and immunoflourescent costaining 
was performed with IgG mouse and DAPI in row 1 and IgG rabbit and DAPI in row 2. 
Images were overlaid and merges are noted. B) Using the same process applied in A, 
THP1 cells underwent immunoflourescent costaining with anti-Na+/K+ ATPase and 
DAPI for nuclear definition. C) C57BL/6 and Rac2KO BMDMs were adhered to poly-l-




































Figure 4: Effect of Atorvastatin on Rac2 localization. THP1 cells subjected to the 
indicated treatment conditions. PMA incubation lasts for 30 minutes and was performed 
prior to cell lysis. Atorvastatin incubation lasted for 24 hours prior to lysis. Lysis was 
performed with separation of cytoplasmic and membrane fractions using thermo 
scientific subcellular fractionation buffers. Samples were incubated with 100%M GTP#S 
for 15 minutes at 37°C before or after subcellular separation as indicated. Anti-Rac2 C-
terminus antibodies were used for detection. Localization markers are provided for 























































































































Figure 5: Characterization of C-terminus and full recombinant Rac2 antibody 
classes. Antibodies directed at C-terminus display isoprenylation dependent binding 
compared to monoclonal antibodies. A) This is a graphical representation of the 
differences between the two major antibodies used in our assays. As shown, the Abcam 
and Santa Cruz antibody are targeted towards the C-terminus of the Rac2 protein which is 
the same location that the isoprenylation modification targets. The Millipore antibody 
was designed to recognize a recombinant form of the Rac2 protein. B). THP1, C57BL/6 
and Rac2KO cells were incubated with 10%M atorvastatin for 24 hours.  Samples were 
then lysed, treated with 100%M GTP#S, and subjected to pulldown with PBD-pak beads 
according to Rac GTPase activation assay. Anti-Rac2 antibodies to the C-terminus 
(Abcam) and full recombinant (Proteintech) Rac2 protein were used for detection by 
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Fig. 1. Structures of the farnesyl-cysteine and gerarylgeranyl-cysteine. 
The isoprenoid is attached via a thioether linkage from the C-l carbon 
to the thiol of the amino acid. 
111. CLASSES OF PRENYLATED PROTEINS 
The increasing awareness that the presence of a CAAX- 
motif at its carboxyl terminus identified a protein as a 
candidate for prenylation prompted a flurry of activity 
directed toward determining the prenylation status of 
such proteins. Searches of the protein sequence data bases 
initially identified - 40 such candidates; surprisingly, 
most of these proteins were members of the class of GTP-  
binding proteins (the so-called “small G proteins”) related 
to the ras proteins. Furthermore, most of the remaining 
candidates (e.g., the y subunits of the heterotrimeric G 
proteins, cGMP phosphodiesterase) were also known to 
be involved in cellular signaling events (1, 18). Essentially 
all of these candidate proteins that have been closely in- 
spected have been shown to be prenylated. To date, only 
the 15-carbon farnesyl and 20-carbon geranylgeranyl 
groups have been found to modify proteins, with geranyl- 
geranyl being the predominant isoprenoid attached (19, 
20). Of considerable interest to those studying the en- 
zymology of the prenylation processes (see below), the 
COOH-terminal amino acid (“X) of the CAAX box is 
now known to specify which isoprenoid is attached to a 
candidate protein. If this residue is a serine, methionine, 
or glutamine residue, the protein contains the farnesyl 
isoprenoid, while a leucine at that position directs ger- 
anylgeranyl addition (2, 21). 
Prenylation is not the only posttranslational modifica- 
tion performed on proteins containing the CAAX-motif. 
Specifically, the mature forms of these prenylated proteins 
lack the three COOH-terminal amino acids (the “AAX). 
A cellular peptidase (see Section VI) removes these three 
amino acids, leaving the prenylated cysteine as the 
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Fig. 2. Biosynthesis of isoprenoids in eukaryotic cells. HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) is 
formed from three molecules of acetyl-coA. The rate-limiting enzyme in the pathway, HMG-CoA reductase, is the 
site of action of the pharmacological agent, mevinolin. 

































































Figure 6: Effect of Rac2 localization in BMDM. BMDM where isolated from femurs 
and tibia of C57BL/6 mice. Cells where incubated in L-cell media  + fully supplemented 
RPMI for 7 days after which they were exposed to 10uM atorvastatin for 24hrs, lysed 
utilized subcellular fraction protocol, and loaded into gel. Western blots were stained 







































































































Figure 7: Effect of β2 integrin engagement and PMA on Rac2 activation. THP1 cells 
were either incubated on Fc coated or ICAM coated plates for 60 minutes with PMA co-
incubation as indicated. GTP#S sample is provided as positive control. Cellular lysis and 
pulldown with PBD-pak beads were performed according to Rac GTPase activation 
assay. Aliquots were taken for total cell lysate (TCL). Anti-Rac2 C-terminus antibody or 
anti-Rac1 antibody was used for protein detection by western blot in pulldown material 

















































Figure 8: Effect of time dependent PMA incubation on complex formation. THP1 
cells were incubated with PMA for 0, 1.5, 5 and 15 minutes as indicated. Cellular lysis 
and pulldown were performed according to Rac GTPase activation assay. Samples were 
run through 4-15% polyacrylamide gel at 200mV for 30minutes. Gel was then stained 
with Coomassie brilliant blue for 1 hour and then destained with destaining solution.  
Indicated bands on polyacrylamide labeled at roughly 40kDa and 200kDa were extracted 




























Figure 9: Mass spectrometry results demonstrate actin and Myosin IIA. A) 41.7 kDa 
band has 78.7% homology with actin. B) 226 kDa band has 61.5% coverage of non-





  1 MDDDIAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK 
 51 DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE  
101 HPVLLTEAPL NPKANREKMT QIMFETFNTP AMYVAIQAVL SLYASGRTTG  
151 IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF  
201 TTTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI  
251 GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS  
301 GGTTMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS  




   1 MAQQAADKYL YVDKNFINNP LAQADWAAKK LVWVPSDKSG FEPASLKEEV 
  51 GEEAIVELVE NGKKVKVNKD DIQKMNPPKF SKVEDMAELT CLNEASVLHN 
 101 LKERYYSGLI YTYSGLFCVV INPYKNLPIY SEEIVEMYKG KKRHEMPPHI 
 151 YAITDTAYRS MMQDREDQSI LCTGESGAGK TENTKKVIQY LAYVASSHKS 
 201 KKDQGELERQ LLQANPILEA FGNAKTVKND NSSRFGKFIR INFDVNGYIV 
 251 GANIETYLLE KSRAIRQAKE ERTFHIFYYL LSGAGEHLKT DLLLEPYNKY  
 301 RFLSNGHVTI PGQQDKDMFQ ETMEAMRIMG IPEEEQMGLL RVISGVLQLG 
 351 NIVFKKERNT DQASMPDNTA AQKVSHLLGI NVTDFTRGIL TPRIKVGRDY 
 401 VQKAQTKEQA DFAIEALAKA TYERMFRWLV LRINKALDKT KRQGASFIGI 
 451 LDIAGFEIFD LNSFEQLCIN YTNEKLQQLF NHTMFILEQE EYQREGIEWN 
 501 FIDFGLDLQP CIDLIEKPAG PPGILALLDE ECWFPKATDK SFVEKVMQEQ 
 551 GTHPKFQKPK QLKDKADFCI IHYAGKVDYK ADEWLMKNMD PLNDNIATLL 
 601 HQSSDKFVSE LWKDVDRIIG LDQVAGMSET ALPGAFKTRK GMFRTVGQLY 
 651 KEQLAKLMAT LRNTNPNFVR CIIPNHEKKA GKLDPHLVLD QLRCNGVLEG 
 701 IRICRQGFPN RVVFQEFRQR YEILTPNSIP KGFMDGKQAC VLMIKALELD 
 751 SNLYRIGQSK VFFRAGVLAH LEEERDLKIT DVIIGFQACC RGYLARKAFA 
 801 KRQQQLTAMK VLQRNCAAYL KLRNWQWWRL FTKVKPLLQV SRQEEEMMAK 
 851 EEELVKVREK QLAAENRLTE METLQSQLMA EKLQLQEQLQ AETELCAEAE 
 901 ELRARLTAKK QELEEICHDL EARVEEEEER CQHLQAEKKK MQQNIQELEE 
 951 QLEEEESARQ KLQLEKVTTE AKLKKLEEEQ IILEDQNCKL AKEKKLLEDR 
1001 IAEFTTNLTE EEEKSKSLAK LKNKHEAMIT DLEERLRREE KQRQELEKTR 
1051 RKLEGDSTDL SDQIAELQAQ IAELKMQLAK KEEELQAALA RVEEEAAQKN 
1101 MALKKIRELE SQISELQEDL ESERASRNKA EKQKRDLGEE LEALKTELED 
1151 TLDSTAAQQE LRSKREQEVN ILKKTLEEEA KTHEAQIQEM RQKHSQAVEE 
1201 LAEQLEQTKR VKANLEKAKQ TLENERGELA NEVKVLLQGK GDSEHKRKKV 
1251 EAQLQELQVK FNEGERVRTE LADKVTKLQV ELDNVTGLLS QSDSKSSKLT 
1301 KDFSALESQL QDTQELLQEE NRQKLSLSTK LKQVEDEKNS FREQLEEEEE 
1351 AKHNLEKQIA TLHAQVADMK KKMEDSVGCL ETAEEVKRKL QKDLEGLSQR 
1401 HEEKVAAYDK LEKTKTRLQQ ELDDLLVDLD HQRQSACNLE KKQKKFDQLL 
1451 AEEKTISAKY AEERDRAEAE AREKETKALS LARALEEAME QKAELERLNK 
1501 QFRTEMEDLM SSKDDVGKSV HELEKSKRAL EQQVEEMKTQ LEELEDELQA 
1551 TEDAKLRLEV NLQAMKAQFE RDLQGRDEQS EEKKKQLVRQ VREMEAELED 
1601 ERKQRSMAVA ARKKLEMDLK DLEAHIDSAN KNRDEAIKQL RKLQAQMKDC 
1651 MRELDDTRAS REEILAQAKE NEKKLKSMEA EMIQLQEELA AAERAKRQAQ 
1701 QERDELADEI ANSSGKGALA LEEKRRLEAR IAQLEEELEE EQGNTELIND 
1751 RLKKANLQID QINTDLNLER SHAQKNENAR QQLERQNKEL KVKLQEMEGT 
1801 VKSKYKASIT ALEAKIAQLE EQLDNETKER QAACKQVRRT EKKLKDVLLQ 
1851 VDDERRNAEQ YKDQADKAST RLKQLKRQLE EAEEEAQRAN ASRRKLQREL 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 10: Effect of atorvastatin complex formation. THP1 cells were incubated with 
0.1, 1, 10 and 100%M of atorvastatin over 24 hour period. Samples were treated with 
100%M GTP#S for 15mins at 37°C, lysed and subjected to pulldown with PBD-pak 
beads. Aliquots were set aside for total cell lysates (TCL). Two polyacrylamide gels were 
run at 200mV for 30 mins. Gel 1 was stained with Coomassie brilliant blue for 1 hour and 
then destained with destaining solution. Image developed on Licor System. Gel 2 was 



































































Figure 11: Effect of GGPP and FPP supplementation on Atorvastatin mediated 
complex inhibition. THP1 cells were incubated with 10%M atorvastatin for 24 hours and 
provided no substrate, 5%M FPP, 5%M GGPP or 5%M FPP + 5%M GGPP as indicated. 
Negative control without statin therapy or PMA is provided. Positive control with PMA 
is provided. Samples were lysed and separated aliquots for pulldown and total cell 
lysates. Pulldown samples were treated with 100%M GTP#S for 15mins at 37°C, and 
subjected to PBD-pak beads. Aliquots were set aside for total cell lysates (TCL). Two 
polyacrylamide gels were run at 200mV for 30 mins. Gel 1 was stained with Coomassie 
brilliant blue for 1 hour and then destained with destaining solution. Image of gel 
developed on Licor system. Gel 2 was transferred to western and stained with anti-Rac2 






















































































Figure 12: Effect of Cytochalasin D on complex formation. THP1 cells were incubated 
with 0.1, 1, and 10%M cytochalasin D and 100ng/mL of CCL2 as indicated. Negative 
control without CCL2 or Cytochalasin D is provided. Positive control with CCL2 is 
provided. Samples were lysed, treated with 100%M GTP#S for 15mins at 37°C, and 
subjected to pulldown with PBD-pak beads according to Rac GTPase activation assay. 
Anti-Rac2 antibodies (full recombinant), anti-actin, and anti-Myosin IIA antibodies were 





































































Figure 13: Effect of Blebbistatin on complex formation. THP1 cells were incubated 
with 2,10, and 50%M blebbistatin as indicated. Negative control is provided with no 
PMA. Positive control is provided with PMA.  Samples were lysed, treated with 100%M 
GTP#S for 15mins at 37°C performed according to Rac GTPase activation assay. 
Samples were run through 4-15% polyacrylamide gel at 200mV for 30mins. Gel was then 
stained with Coomassie brilliant blue for 1 hour and then destained with destaining 
















































Figure 14: Knockdown of Rac2 Myosin IIA interaction in Rac2KO BMDMs. BMDM 
from C56BL/6 and Rac2KO are exposed to CCL2. Samples were lysed, treated with 
100uM GTP#S for 15mins at 37°C, and subjected to pulldown with PBD-pak beads 
according to Rac GTPase activation assay. Anti-Rac2 (full recombinant), anti-Rac1, and 
anti-CDC42 antibodies were used to detect respective proteins by western blot. Total cell 
lysates (TCL) are provided.   
 
PBD-Associated Myosin IIA 













































Figure 15: Effect of PMA and history of current statin use on complex formation in 
human derived peripheral WBC’s. Human monocytes were isolated from whole blood 
in heparinized tubes from 4 volunteers who varied by gender and statin usage. Whole 
blood was fractionated by centrifugation for 30 minutes at 900g. Mononuclear 
lymphocyte cell layer was isolated, added to HBSS solution and re-suspended in RPMI-
1640. Cells were then stimulated with PMA for 30 minutes, lysed, treated with 100%M 
GTP#S for 15 minutes at 37°C, denatured in sample buffer and run through 4-15% 
polyacrylamide gel at 200mV for 30 minutes. Gel was then stained with Coomassie 
brilliant blue for 1 hour and then destained with destaining solution. Image was 


























































































Figure 16: Characterization of time to loss of isoprenylation with Atorvastatin. A) 
THP1 cells were incubated with 10%M Atorvastatin for 0, 1.5, 3, 6, 12, 24 and 48 hours. 
The first sample group was lysed, subjected to pulldown with PBD-pak beads according 
to Rac GTPase activation assay. The second sample group was lysed, treated with 100%M 
GTP#S for 15mins at 37°C, and subjected to pulldown with PBD-pak beads according to 
Rac GTPase activation assay. Anti-Rac2 antibodies to the c-terminal (Abcam) and full 
(Millipore) recombinant Rac2 protein were used for detection by western blot as 
indicated. B) Quantification of ratio of pulldown +/- GTP#S to loading control is 
provided.  
 
























































































































Figure 17: Effect of Atorvastatin on β2 integrin engagement and PMA induced 
HuR translocation. THP1 cells were adhered to either poly-l-lysine or ICAM coated 
coverslips and incubated in PMA or Atorvastatin 10%M for 24 hours as indicated. These 
cells were then permeabilized, and immunoflourescent costaining was performed with 























Figure 18: Effect of Rac2 isoprenylation state on Rac2-Myosin IIA interaction and 
subsequent HuR translocation. A) THP1 cells were incubated with 10%M Atorvastatin 
for 24 hours and were terminally incubated with CCL2 for 15 minutes. Samples were 
provided no precursor, squalene, FPP, or GGPP over the 24 hours prior to lysis as 
indicated. Samples were lysed, treated with 100%M GTP#S for 15 minutes at 37°C and 
subjected to pulldown with PBD-pak beads according to Rac GTPase activation assay. B) 
Samples with same treatment from conditions if figure A were fixed and stained for 
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Figure 19: Effect of β2 integrin engagement and CCL2 on Rac2 interaction with 
Myosin IIA. Human monocyte cells are incubated with PMA and 100mg/mL of MCP1 
for 15 minutes. Samples were lysed and subjected to pulldown with PBD-pak beads 
according to Rac GTPase activation assay. Anti-Rac2 (full recombinant) and anti-Myosin 





































































Figure 20: Characterization of CCL2 coupled B2 integrin engagement on Rac2 
Myosin IIA interaction as determined by proximity ligation assay. Samples are 
subjected to CCL2 alone, ICAM alone and CCL2+ICAM as indicated. Cells were fixed 
to coverslips, permeabilized, and stained with anti-Rac2 (full recombinant) and anti-
Myosin IIA. A PLA probe was then utilized in conjunction with a ligation-ligase solution 
to hybridize the two PLA probes in close proximity. An amplification solution containing 
fluorescently labeled oligonucleotides was provided with polymerase allowing the 
creation of a rolling circle amplification product signal detected by microscopy. 





































Figure 22: Significance of Rac2 in Chemokine-coupled !2 Integrin-induced HuR  
Translocation. A) BMDM isolated from C57BL/6 and RAC2KO are subjected to 
CCL2+ICAM. B) Quantitative analysis of HuR translocation by translocation factor and 















Figure 23: Significance of Myosin IIA in Chemokine-coupled !2 Integrin-induced 
HuR Translocation. A) BMDM from myosin knockout and heterozygous mice are 
subjected to ICAM+CCL2 or CCL2 alone stimulation. Samples are stained with DAPI, 
HuR, and actin and subfigures are merged. B) Quantitative analysis of HuR translocation 
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